<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35733875</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Case Report: Pirfenidone in the Treatment of Post-COVID-19 Pulmonary Fibrosis.</ArticleTitle><Pagination><StartPage>925703</StartPage><MedlinePgn>925703</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">925703</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2022.925703</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Pulmonary fibrosis is one of the sequelae of the COVID-19, which seriously affects the quality of life of survivors. Currently, there are no optimal evidence based guidelines targeting this population.</AbstractText><AbstractText Label="CASE PRESENTATION" NlmCategory="UNASSIGNED">We report a 66-year-old female patient without underlying comorbidities admitted to Changsha Public Health Center because of COVID-19. During hospitalization, she developed co-bacterial infection and acute respiratory distress syndrome, and received broad-spectrum antibacterial therapy, invasive mechanical ventilation and extracorporeal membrane oxygenation. After the acute phase, she developed post-COVID-19 pulmonary fibrosis subsequently treated with pirfenidone. Over 96 weeks after pirfenidone treatment, her modified Medical Research Council Dyspnea level improved to 2 from 4 at discharge. Her 6 minutes walk test distance, total lung capacity, and diffusion capacity for carbon monoxide all increased. Chest CT performed on 2 years after illness onset showed regressing fibrosis. The Hospital Anxiety and Depression Scale, Athens Insomnia Scale, and 36-Item Short Form Health Survey questionnaire all improved.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Post-COVID-19 pulmonary fibrosis is a challenging consequence of COVID-19, and our case suggests that pirfenidone may be an effective treatment option.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Zhou, Yang, Kong, Wei, LvQiu, Wang, Lin, Yin, Zhou and Luo.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xianglin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, the Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Unit of Respiratory Disease, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunan Diagnosis and Treatment Center of Respiratory Disease, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Danhui</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, the Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Unit of Respiratory Disease, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunan Diagnosis and Treatment Center of Respiratory Disease, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Xianglong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Respiratory Medicine, The First Hospital of Changsha, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Chengli</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, the Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Unit of Respiratory Disease, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunan Diagnosis and Treatment Center of Respiratory Disease, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>LvQiu</LastName><ForeName>Siqi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, the Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Unit of Respiratory Disease, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunan Diagnosis and Treatment Center of Respiratory Disease, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, the Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Unit of Respiratory Disease, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunan Diagnosis and Treatment Center of Respiratory Disease, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yongkang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, the Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Unit of Respiratory Disease, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunan Diagnosis and Treatment Center of Respiratory Disease, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Zhilan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Radiology, The Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Zhiguo</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Respiratory Medicine, The First Hospital of Changsha, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, the Second Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Unit of Respiratory Disease, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunan Diagnosis and Treatment Center of Respiratory Disease, Changsha, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">pirfenidone</Keyword><Keyword MajorTopicYN="N">post-COVID-19</Keyword><Keyword MajorTopicYN="N">pulmonary fibrosis</Keyword><Keyword MajorTopicYN="N">sequelae</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>23</Day><Hour>2</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35733875</ArticleId><ArticleId IdType="pmc">PMC9207265</ArticleId><ArticleId IdType="doi">10.3389/fmed.2022.925703</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization . Coronavirus disease 2019 (COVID-19) situation report. 2022. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports (accessed April 2, 2022).</Citation></Reference><Reference><Citation>Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. (2020) 324:782&#x2013;93. 10.1001/jama.2020.12839</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12839</ArticleId><ArticleId IdType="pubmed">32648899</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan WJ Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. . Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. (2020) 382:1708&#x2013;20. 10.1056/NEJMoa2002032</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Liu X, Zhou Y, Yu H, Li R, Zhan Q, et al. . 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. (2021) 9:747&#x2013;54. 10.1016/S2213-2600(21)00174-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00174-0</ArticleId><ArticleId IdType="pmc">PMC8099316</ArticleId><ArticleId IdType="pubmed">33964245</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin X, Xi X, Min X, Feng Z, Li B, Cai W, et al. . Long-term chest CT follow-up in COVID-19 Survivors: 102-361 days after onset. Ann Transl Med. (2021) 9:1231. 10.21037/atm-21-1438</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm-21-1438</ArticleId><ArticleId IdType="pmc">PMC8421980</ArticleId><ArticleId IdType="pubmed">34532368</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Yao Q, Gu X, Wang Q, Ren L, Wang Y, et al. . 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. (2021) 398:747&#x2013;58. 10.1016/S0140-6736(21)01755-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01755-4</ArticleId><ArticleId IdType="pmc">PMC8389999</ArticleId><ArticleId IdType="pubmed">34454673</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei P, Fan B, Mao J, Wei J, Wang P. The progression of computed tomographic (CT) images in patients with coronavirus disease (COVID-19) pneumonia: running title: The CT progression of COVID-19 pneumonia, J Infect. (2020) 80:e30&#x2013;1. 10.1016/j.jinf.2020.03.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.03.020</ArticleId><ArticleId IdType="pmc">PMC7195117</ArticleId><ArticleId IdType="pubmed">32205140</ArticleId></ArticleIdList></Reference><Reference><Citation>Faverio P, Luppi F, Rebora P, Andrea G, Stainer A, et al. . 1-year pulmonary impairment after severe COVID-19: a prospective, multicenter follow-up study. Respir Res. (2022) 23:65. 10.1186/s12931-022-01994-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-022-01994-y</ArticleId><ArticleId IdType="pmc">PMC8934910</ArticleId><ArticleId IdType="pubmed">35313890</ArticleId></ArticleIdList></Reference><Reference><Citation>Cocconcelli E, Bernardinello N, Giraudo C, Castelli G, Giorgino A, Leoni D, et al. . Characteristics and prognostic factors of pulmonary fibrosis after COVID-19 pneumonia. Front Med. (2021) 8:823600. 10.3389/fmed.2021.823600</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.823600</ArticleId><ArticleId IdType="pmc">PMC8841677</ArticleId><ArticleId IdType="pubmed">35174188</ArticleId></ArticleIdList></Reference><Reference><Citation>Naeije R, Caravita S. Phenotyping long COVID. Eur Respir J. (2021) 58:1763. 10.1183/13993003.01763-2021</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01763-2021</ArticleId><ArticleId IdType="pmc">PMC8287735</ArticleId><ArticleId IdType="pubmed">34244323</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. BMJ. (2021) 374:n1648. 10.1136/bmj.n1648</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. . Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. (2014) 370:2071&#x2013;82. 10.1056/NEJMoa1402584</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1402584</ArticleId><ArticleId IdType="pubmed">24836310</ArticleId></ArticleIdList></Reference><Reference><Citation>King TE, Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. . A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. (2014) 370:2083&#x2013;92. 10.1056/NEJMoa1402582</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1402582</ArticleId><ArticleId IdType="pubmed">24836312</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, et al. . Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med. (2017) 5:33&#x2013;41. 10.1016/S2213-2600(16)30326-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(16)30326-5</ArticleId><ArticleId IdType="pubmed">27876247</ArticleId></ArticleIdList></Reference><Reference><Citation>China National Health Commission (NHC) . Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (4th edition). Available online at: http://www.nhc.gov.cn/ (accessed April 2, 2022).</Citation></Reference><Reference><Citation>Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. (2021) 18:e1003773. 10.1371/journal.pmed.1003773</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003773</ArticleId><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Z, Tang N, Chen Y, Ma L, Wei Y, Lu Y, et al. . CT features of COVID-19 patients with two consecutive negative RT-PCR tests after treatment. Sci Rep. (2020) 10:11548. 10.1038/s41598-020-68509-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-68509-x</ArticleId><ArticleId IdType="pmc">PMC7360570</ArticleId><ArticleId IdType="pubmed">32665633</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L, Liu Y, Fan B, Xiao Y, Tian Q, Chen L, et al. . Dynamic changes of serum SARS-coronavirus IgG, pulmonary function and radiography in patients recovering from SARS after hospital discharge. Respir Res. (2005) 6:5. 10.1186/1465-9921-6-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1465-9921-6-5</ArticleId><ArticleId IdType="pmc">PMC545044</ArticleId><ArticleId IdType="pubmed">15638943</ArticleId></ArticleIdList></Reference><Reference><Citation>Das KM, Lee EY, Singh R, Enani MA, Al Dossari K, Van Gorkom K, et al. . Follow-up chest radiographic findings in patients with MERS-CoV after recovery. Indian J Radiol Imaging. (2017) 27:342&#x2013;9. 10.4103/ijri.IJRI_469_16</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijri.IJRI_469_16</ArticleId><ArticleId IdType="pmc">PMC5644332</ArticleId><ArticleId IdType="pubmed">29089687</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo X, Jian W, Su Z, Chen M, Peng H, Peng P, et al. . Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur Respir J. (2020) 2020:55. 10.1183/13993003.01217-2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01217-2020</ArticleId><ArticleId IdType="pmc">PMC7236826</ArticleId><ArticleId IdType="pubmed">32381497</ArticleId></ArticleIdList></Reference><Reference><Citation>Frija-Masson J, Debray MP, Gilbert M, Lescure FX, Travert F, Borie R, et al. . Functional characteristics of patients with SARS-CoV-2 pneumonia at 30 days post-infection. Eur Respir J. (2020) 2020:56. 10.1183/13993003.01754-2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01754-2020</ArticleId><ArticleId IdType="pmc">PMC7301832</ArticleId><ArticleId IdType="pubmed">32554533</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, et al. . Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. (2010) 35:821&#x2013;9. 10.1183/09031936.00005209</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.00005209</ArticleId><ArticleId IdType="pubmed">19996196</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. . Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. (2011) 377:1760&#x2013;9. 10.1016/S0140-6736(11)60405-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(11)60405-4</ArticleId><ArticleId IdType="pubmed">21571362</ArticleId></ArticleIdList></Reference><Reference><Citation>Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, et al. . Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. (2020) 8:147&#x2013;57. 10.1016/S2213-2600(19)30341-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(19)30341-8</ArticleId><ArticleId IdType="pubmed">31578169</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F, Wei Y, He L, Zhang H, Hu Q, Yue H, et al. . A trial of pirfenidone in hospitalized adult patients with severe coronavirus disease 2019. Chin Med J. (2021) 135:368&#x2013;70. 10.1097/CM9.0000000000001614</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CM9.0000000000001614</ArticleId><ArticleId IdType="pmc">PMC8812696</ArticleId><ArticleId IdType="pubmed">34855641</ArticleId></ArticleIdList></Reference><Reference><Citation>Phase-II Randomized Clinical Trial to Evaluate the Effect of Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis; Identifier NCT04607928; Available online at: https://clinicaltrials.gov/ (accessed April 2, 2022).</Citation></Reference><Reference><Citation>A Study of the Efficacy and Safety of Pirfenidone vs. Nintedanib in the Treatment of Fibrotic Lung Disease After Coronavirus Disease-19 Pneumonia; Identifier NCT04856111; Available online at: https://clinicaltrials.gov/ (accessed April 2, 2022).</Citation></Reference><Reference><Citation>A Phase 2 Randomized, Double-blind, Placebo-controlled Trial and Open Label Extension to Evaluate the Safety and Efficacy of Deupirfenidone (LYT-100) in Post-acute COVID-19 Respiratory Disease; Identifier NCT04652518; Available online at: https://clinicaltrials.gov/ (accessed April 2, 2022).</Citation></Reference><Reference><Citation>Efficacy and Safety of Pirfenidone in the Treatment of Severe Post-Novel Coronavirus Pneumonia (COVID-19) Fibrosis:a prospective exploratory experimental medical study; Identifier ChiCTR2000030892; Available online at: https://www.chictr.org.cn (accessed April 2, 2022).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>